Marco Heestermans, Charles-Antoine Arthaud, Amelie Prier, Marie-Ange Eyraud, Hind Hamzeh-Cognasse, Fabrice Cognasse, Anne-Claire Duchez
{"title":"Association of high mobility group box 1 (HMGB1) levels with donor's age, sex and ABO blood group in single-donor apheresis platelet concentrates.","authors":"Marco Heestermans, Charles-Antoine Arthaud, Amelie Prier, Marie-Ange Eyraud, Hind Hamzeh-Cognasse, Fabrice Cognasse, Anne-Claire Duchez","doi":"10.1111/vox.70033","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>High mobility group box 1 (HMGB1) is a nuclear protein expressed by various cell types and recognized as a damage-associated molecular pattern (DAMP). DAMPs play a pivotal role in driving inflammatory responses. Platelet-derived HMGB1 has been associated with severe adverse reactions following platelet concentrate transfusions, underscoring its clinical relevance. This study investigated whether HMGB1 levels in single-donor apheresis platelet concentrates (SDA-PCs) are influenced by routinely documented donor characteristics, such as age, sex and ABO blood group.</p><p><strong>Materials and methods: </strong>We analysed HMGB1 levels in 190 unpaired SDA-PC units. Donor characteristics, that is, age, sex and ABO blood group were obtained from routine records and examined for associations with HMGB1 levels.</p><p><strong>Results: </strong>HMGB1 levels showed no significant correlation with donor age or ABO blood group. However, levels were modestly lower in SDA-PC units derived from female donors compared to male donors.</p><p><strong>Conclusion: </strong>These findings reveal donor-specific variability in HMGB1 levels, particularly regarding donor sex, and underscore the need to systematically document donor demographic and biological characteristics during blood donation. Such data could enhance our understanding of donor-related factors influencing transfusion outcomes.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: High mobility group box 1 (HMGB1) is a nuclear protein expressed by various cell types and recognized as a damage-associated molecular pattern (DAMP). DAMPs play a pivotal role in driving inflammatory responses. Platelet-derived HMGB1 has been associated with severe adverse reactions following platelet concentrate transfusions, underscoring its clinical relevance. This study investigated whether HMGB1 levels in single-donor apheresis platelet concentrates (SDA-PCs) are influenced by routinely documented donor characteristics, such as age, sex and ABO blood group.
Materials and methods: We analysed HMGB1 levels in 190 unpaired SDA-PC units. Donor characteristics, that is, age, sex and ABO blood group were obtained from routine records and examined for associations with HMGB1 levels.
Results: HMGB1 levels showed no significant correlation with donor age or ABO blood group. However, levels were modestly lower in SDA-PC units derived from female donors compared to male donors.
Conclusion: These findings reveal donor-specific variability in HMGB1 levels, particularly regarding donor sex, and underscore the need to systematically document donor demographic and biological characteristics during blood donation. Such data could enhance our understanding of donor-related factors influencing transfusion outcomes.
期刊介绍：
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
